Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging
Condition(s) studied
Study summary
This prospective diagnostic accuracy study compares computed tomography (CT) and multiparametric magnetic resonance imaging (MRI) using the Vesical Imaging-Reporting and Data System (VI-RADS) for local staging of newly diagnosed bladder cancer. All participants undergo both imaging modalities prior to transurethral resection of the bladder tumor (TURBT) or cystectomy. Histopathology serves as the reference standard.
Eligibility
Primary outcome measure(s)
- Diagnostic Accuracy for Detection of Muscle-Invasive Bladder Cancer (≥T2) — From imaging to final histopathological reference standard (up to 12 months)
The primary outcome is the diagnostic accuracy of multiparametric magnetic resonance imaging (MRI) using the Vesical Imaging-Reporting and Data System (VI-RADS) compared with contrast-enhanced computed tomography (CT) for the detection of muscle-invasive bladder cancer (pathological stage ≥T2). Sensitivity and specificity will be calculated using histopathology from transurethral resection of the bladder tumor, re-TURBT, and/or cystectomy as the reference standard.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Oslo University Hospital | Oslo | Norway | Recruiting |
More Oslo University Hospital trials in Norway
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07602010 on ClinicalTrials.gov ↗ ← All trials in Norway